Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012
Taxane-induced neuropathy not tied to breast cancer outcome
For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical Oncology.

Bryan P. Schneider, M.D., of the Eastern Cooperative Oncology Group in Indianapolis, and colleagues conducted a study involving 4,554 women with operable who received chemotherapy (up to four cycles of doxorubicin and cyclophosphamide every three weeks) followed by either paclitaxel every three weeks for four cycles (P3), paclitaxel weekly for 12 cycles (P1), docetaxel every three weeks for four cycles (D3), or docetaxel every week for 12 cycles (D1).

The researchers found that grade 2 to 4 neuropathy occurred in 18, 22, 15, and 13 percent of patients who received at least one taxane dose in the P3, P1, D3, and D1 arms of the study, respectively. No significant relationship was observed between the development of neuropathy and disease-free survival, overall survival, or recurrence-free survival, in a model including age, race, obesity, menopausal status, , nodal status, treatment group, neuropathy, and hyperglycemia.

"Taxane-induced does not correlate with improved outcomes in patients with operable breast cancer treated with adjuvant taxane therapy," the authors write. "This finding provides reassurance that biomarkers predictive for neuropathy will likely not enrich for patients who are more likely to benefit from taxane therapy and may also be useful for the identification of patients who are most likely to benefit from adjunctive therapies to mitigate neuropathy."

Several authors disclosed to the pharmaceutical industry.

Explore further: FDA OKs Ixempra for advanced breast cancer

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

FDA OKs Ixempra for advanced breast cancer

October 22, 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

Docetaxel given after doxorubicin reduces recurrence

January 8, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National ...

Recommended for you

Molecularly shutting down cancer cachexia

August 30, 2016

Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme ...

Radiologists detect breast cancer in 'blink of an eye'

August 29, 2016

A new study by investigators at Brigham and Women's Hospital in collaboration with researchers at the University of York and Leeds in the UK and MD Andersen Cancer Center in Texas puts to the test anecdotes about experienced ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.